CIK 924020
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2021-Q1. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 84.72% | 9 |
| Health Care Equipment & Supplies | 10.17% | 3 |
| Unclassified | 5.11% | 9 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | FATE | FATE THERAPEUTICS INC | Health Care | 29.98% |
| 2 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Health Care | 27.61% |
| 3 | PTGX | Protagonist Therapeutics, Inc | Health Care | 11.24% |
| 4 | CVRX | CVRx, Inc. | Health Care | 10.01% |
| 5 | LEGN | Legend Biotech Corp | Health Care | 6.84% |
| 6 | MGTX | MeiraGTx Holdings plc | Health Care | 4.59% |
| 7 | FUSION PHARMACEUTICALS INC | Unclassified | 3.03% | |
| 8 | VOR | Vor Biopharma Inc. | Health Care | 2.05% |
| 9 | PHGE | BiomX Inc. | Health Care | 1.19% |
| 10 | THERAPEUTICS ACQUISITION COR | Unclassified | 1.05% |
12/21 names classified · sector 94.9% of weight · industry 94.9% · mkt cap 88.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 94.9% of the book is sector-classified (unclassified names shown, never dropped).
Only 1% of book weight classified — the grid is NOT representative of the whole book.
Classified: 1.2% of book weight (1/13 names) · unclassified 98.8%: FATE, ARWR, PTGX, CVRX, LEGN, , MGTX, VOR, ACET, ALDX +2 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | FATEFATE THERAPEUTICS INC | 3,379,064 | $293M | 30.0% | HOLD |
| 2 | ARWRARROWHEAD PHARMACEUTICALS IN | 3,260,869 | $270M | 27.6% | HOLD |
| 3 | PTGXPROTAGONIST THERAPEUTICS INC | 2,449,183 | $110M | 11.2% | HOLD |
| 4 | CVRXCVRX INC | 3,495,575 | $98M | 10.0% | NEW |
| 5 | LEGNLEGEND BIOTECH CORP | 1,629,173 | $67M | 6.8% | HOLD |
| 6 | MGTXMEIRAGTX HLDGS PLC | 2,898,550 | $45M | 4.6% | HOLD |
| 7 | FUSION PHARMACEUTICALS INC | 3,670,516 | $30M | 3.0% | HOLD |
| 8 | VORVOR BIOPHARMA INC | 1,074,658 | $20M | 2.0% | HOLD |
| 9 | PHGEBIOMX INC | 2,133,402 | $12M | 1.2% | HOLD |
| 10 | THERAPEUTICS ACQUISITION COR | 1,000,000 | $10M | 1.1% | NEW |
| 11 | ACETADICET BIO INC | 728,944 | $8M | 0.8% | HOLD |
| 12 | PHASEBIO PHARMACEUTICALS INC | 1,607,044 | $6M | 0.6% | HOLD |
| 13 | ALDXALDEYRA THERAPEUTICS INC | 394,834 | $4M | 0.5% | HOLD |
| 14 | CASTLIGHT HEALTH INC CL B | 811,295 | $2M | 0.2% | HOLD |
| 15 | NPCENEUROPACE INC | 55,435 | $1M | 0.1% | NEW |
| 16 | ZYMERGEN INC | 16,553 | $662,000 | 0.1% | NEW |
| 17 | TRACON PHARMACEUTICALS INC | 84,003 | $545,000 | 0.1% | HOLD |
| 18 | CATALYST BIOSCIENCES INC | 66,951 | $290,000 | 0.0% | HOLD |
| 19 | GRAYBUG VISION INC | 49,547 | $269,000 | 0.0% | HOLD |
| 20 | LUNGPULMONX CORP | 5,639 | $249,000 | 0.0% | HOLD |
| 21 | SENSEONICS HLDGS INC | 54,621 | $210,000 | 0.0% | TRIM −89% |
Where this firm's principals came from and which firms its alumni went on to found.
